The Federal Trade Commission has announced what it calls a major antitrust settlement with Caremark, resolving a closely watched case against one of the country’s largest pharmacy benefit managers. Even without the full settlement details in hand, the development is important: it signals that the FTC is continuing to press competition theories aimed at the role PBMs play in drug pricing, formulary design, and pharmacy reimbursement.

For antitrust and healthcare lawyers, the significance goes well beyond a single company.

The FTC has announced a significant settlement with Caremark Rx LLC and Zinc Health Services LLC in its insulin-pricing antitrust matter, marking one of the clearest signals yet that pharmacy benefit manager rebate structures remain a top enforcement priority. According to the agency, the deal is designed to reduce patients’ out-of-pocket costs, increase transparency, and curb rebate practices that allegedly contributed to higher insulin list prices.

The proceeding, Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin), is part of the FTC’s broader challenge to how major drug middlemen negotiate formularies, rebates, and placement decisions for high-demand medications.